Endocrine Abstracts

Acromegaly is a chronic disease caused almost invariably by a pituitary GH-secreting adenoma leading to overproduction of insulin-like growth factor I (IGF-I). The long-term hypersecretion leads to many comorbidities, as diabetes mellitus, arterial hypertension, and cardiovascular and/or pulmonary disease (including sleep apnea), which are related to an increased mortality rate. In fact, uncontrolled acromegaly is associated with a three times mortality rate as compared with n...

Introduction: High affinity binding of pasireotide for both sst2 and sst5 leads to its enhanced efficacy in treatment of acromegaly but results in decreased secretion of insulin, incretins (GLP-1 and GIP) and, to a lesser extent, glucagon. Metformin may be a good option in patients with acromegaly experiencing hyperglycaemia with pasireotide as it improves GLP-1 secretion. We analysed data from a 12-month, Phase III, randomised study in medically naï...

Introduction: The PAOLA study in patients with inadequately-controlled acromegaly (n=198) demonstrated superior efficacy of pasireotide long-acting release (LAR; 40 mg/60 mg) in biochemical control (GH <2.5 μg/l and normalized IGF-1) vs continued treatment with octreotide LAR 30 mg/lanreotide Autogel 120 mg (15.4% and 20.0% vs 0%). Here we report preliminary data from the extension phase of PAOLA at wk28.Methods: Pasireotide-LAR (40 mg/...